data + articles · 3 listed
newest 2016spec sheet11 rows
A4 Amyloid Beta Amyloid beta (Aβ), historically called the A4 peptide, is a short peptide of roughly 36 to 43 amino acids best known as the principal constituent of the amyloid plaques found in the brains of people with Alzheimer's disease. It is produced naturally in the body through enzymatic cleavage of a larger membrane protein, and its accumulation and aggregation are central to the leading theory of how Alzheimer's disease develops.
- Important research and diagnostic biomarker
- Central to Alzheimer's drug development
- Informs understanding of neurodegeneration
- Aβ is an endogenous, disease-associated peptide rather than a supplement, so it is not something a person takes
- Its accumulation is strongly linked to Alzheimer's disease pathology
- The soluble oligomeric forms are considered the most synaptotoxic
- The presence of plaques does not always cause dementia, so its role is complex
- It is studied mainly as a biomarker and drug target, not as a therapeutic agent
Overview
Amyloid beta is not a manufactured supplement but an endogenous peptide fragment. It was purified and characterized in the mid-1980s from the plaque cores of Alzheimer's disease and Down syndrome brains, where it was identified as a small polypeptide of about 4 kilodaltons; this size gave rise to the historical name A4 [1]. The peptide is excised from a much larger parent molecule, the amyloid precursor protein (APP), and occurs in several length variants, most notably Aβ40 and the more aggregation-prone Aβ42 [2][3].
Aβ is generated by the sequential action of two enzymes, β-secretase and γ-secretase, working on APP [2]. The amyloid hypothesis, first articulated in the early 1990s, proposes that an imbalance between the production and clearance of Aβ, especially Aβ42, is an early and driving event in Alzheimer's disease, with downstream consequences that include tau pathology and neurofibrillary tangles [2][3]. Support for this view includes the finding that inherited early-onset Alzheimer's is caused by mutations in APP or in the presenilin component of γ-secretase, and that people with Down syndrome, who carry an extra copy of the APP gene, develop Aβ deposits early in life [3].
Attention has increasingly shifted from insoluble plaques toward soluble Aβ oligomers, which can impair synaptic function, inhibit long-term potentiation, and disrupt memory in experimental models, and which may spread their misfolded shape in a self-templating manner [3]. At the same time the relationship is not simple; many people accumulate plaques without developing dementia, and Aβ appears to have normal physiological roles that may include antimicrobial defense and modulation of neuronal signaling [3]. Because Aβ is a disease-associated peptide rather than a consumer compound, it is studied chiefly as a biomarker (for example in cerebrospinal fluid and by amyloid-PET imaging) and as a therapeutic target, with several antibody treatments developed to clear it [3].
Mechanism
Amyloid beta arises from proteolytic processing of the amyloid precursor protein (APP), a transmembrane protein. In the amyloidogenic pathway, β-secretase cleaves APP first, and γ-secretase, whose catalytic core is presenilin, then cuts within the membrane to release Aβ peptides of varying length [1][2][3]. The longer Aβ42 form is more hydrophobic and more prone to misfold and self-assemble, progressing from monomers to soluble oligomers and eventually to the fibrils that make up plaque cores [1][3]. Soluble oligomers are now regarded as an especially toxic species; experimental work shows they can reduce number, block , enhance long-term depression, promote tau hyperphosphorylation, and impair memory [3]. Aβ can also seed further misfolding of normal Aβ, a chain-reaction behavior likened to prion propagation [3].
receptor fingerprint
Amyloid precursor protein processingproduct of cleavage
functiondisrupts at high levels
promotes
Tau pathologyupstream driver
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
This is not a supplement and should not be taken; the peptide is associated with neurotoxicity and neurodegeneration. Any legitimate contact with it is in a research or diagnostic context. There is no established safe supplemental use.
Resources
This entry is here for reference.
Research
- 1985first citedAmyloid plaque core protein in Alzheimer disease and Down syndrome
- 2016most recentThe amyloid hypothesis of Alzheimer's disease at 25 years
- 1.Amyloid plaque core protein in Alzheimer disease and Down syndrome
- 2.The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics
- 3.The amyloid hypothesis of Alzheimer's disease at 25 years
3 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Can I take amyloid beta to boost memory?
No. It is the peptide that accumulates in Alzheimer's disease; the goal in medicine is to reduce it, not supplement it.
Does it have any normal function?
At low physiological levels it may play roles in synaptic regulation and immune defense, but its notoriety comes from pathological buildup.
Why is it in a supplement list?
It appears as a research peptide of interest, but it is informational only and not something to dose.
What drugs target it?
Anti-amyloid antibodies and secretase-modulating drugs are designed to clear or reduce it.
Is the amyloid hypothesis settled?
No, it is still debated; amyloid is clearly involved but the full picture of Alzheimer's is more complex.
Adverse effects
- Aβ is an endogenous, disease-associated peptide rather than a supplement, so it is not something a person takes
- Its accumulation is strongly linked to Alzheimer's disease pathology
- The soluble oligomeric forms are considered the most synaptotoxic
- The presence of plaques does not always cause dementia, so its role is complex
- It is studied mainly as a biomarker and drug target, not as a therapeutic agent